Buy VSTM by Jul 27, 2026.

I’ve spent the day digging through AI-driven data, and the bull case for VSTM's commercial-stage drug is incredibly compelling. We’re looking at a target population of over 2,000 KRAS-mutated patients. At an annual cost of $500,000 per patient, in a disease where the recurrence rate is over 80% and traditional chemotherapy offers a dismal 10% ORR, VSTM’s \~44% ORR gives it a near-monopoly in this niche Once insurance coverage fully kicks in and scaling begins, even with a conservative estimate …